Patents Assigned to PHARMAFOX THERAPEUTICS AG
  • Muscle performance improvement compounds comprising C-terminus agrin fragment and an ACTR2B inhibitor
    Patent number: 11407799
    Abstract: A compound comprising at least two components, a first component being the nLG3 or (h)nLG3 domain from the C-terminus of mouse or human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities. Such compounds are effective treatments for neuromuscular diseases and problems.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 9, 2022
    Assignee: PHARMAFOX THERAPEUTICS AG
    Inventors: Jan Willem Vrijbloed, Marina Maria Boido, Olena Butenko, Roberta Schellino